{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:51Z","timestamp":1790906271560,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011599","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000}}],"reference-count":60,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011599.pub2","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T13:10:56Z","timestamp":1524057056000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema"],"prefix":"10.1002","volume":"2018","author":[{"given":"Hemal","family":"Mehta","sequence":"first","affiliation":[{"name":"Royal Free London NHS Foundation Trust; London UK"},{"name":"University of Sydney; Macular Research Group, Save Sight Institute; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hennings","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Gillies","sequence":"additional","affiliation":[{"name":"University of Sydney; Macular Research Group, Save Sight Institute; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Sydney; Macular Research Group, Save Sight Institute; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campain","sequence":"additional","affiliation":[{"name":"University of Sydney; Macular Research Group, Save Sight Institute; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[{"name":"University of Sydney; Macular Research Group, Save Sight Institute; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD011599.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0002|cit2","unstructured":"NCT01945866 Phase II combination steroid and anti-VEGF for persistent DME clinicaltrials.gov\/ct2\/show\/NCT01945866"},{"issue":"2","key":"10.1002\/14651858.CD011599.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000331935","article-title":"Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"227","author":"Lim","year":"2012","journal-title":"Ophthalmologica"},{"issue":"8","key":"10.1002\/14651858.CD011599.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/IAE.0000000000000533","article-title":"A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-VEGF Injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy","volume":"35","author":"Maturi","year":"2015","journal-title":"Retina"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0005|cit5","unstructured":"NCT00737971 Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD) clinicaltrials.gov\/ct2\/show\/NCT00737971"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3928\/23258160-20170829-08","article-title":"Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema","volume":"48","author":"Neto","year":"2017","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0007|cit7","first-page":"1","article-title":"Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"37","author":"Riazi-Esfahani","year":"2017","journal-title":"International Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011599.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00417-007-0688-0","article-title":"Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial","volume":"246","author":"Ahmadieh","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011599.pub2-BIB0009|cit9","first-page":"99","article-title":"Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial","volume":"8","author":"Shoeibi","year":"2013","journal-title":"Journal of Ophthalmic and Vision Research"},{"issue":"2","key":"10.1002\/14651858.CD011599.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/IAE.0b013e31822f55de","article-title":"Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema","volume":"32","author":"Soheilian","year":"2012","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","article-title":"Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema","volume":"116","author":"Soheilian","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011599.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/2008-322X.150818","article-title":"Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial","volume":"9","author":"Yaseri","year":"2014","journal-title":"Journal of Ophthalmic and Vision Research"},{"issue":"3","key":"10.1002\/14651858.CD011599.pub2-BIB0013|cit13","first-page":"841","article-title":"Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema","volume":"35","author":"Synek","year":"2011","journal-title":"Collegium Antropologicum"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/112067210801800614","article-title":"Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema","volume":"18","author":"Faghihi","year":"2008","journal-title":"European Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011599.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1442-9071.2011.02504.x","article-title":"Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema","volume":"39","author":"Sheth","year":"2011","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":"Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"issue":"3","key":"10.1002\/14651858.CD011599.pub2-BIB0017|cit17","first-page":"352","article-title":"Intravitreal bevacizumab combined with\/without triamcinolone acetonide in single injection for treatment of diabetic macular edema","volume":"124","author":"Wang","year":"2011","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00417-017-3819-2","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema","volume":"256","author":"Yu","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0019|cit19","unstructured":"NCT03126786 Suprachoroidal CLS-TA with intravitreal aflibercept versus aflibercept alone in subject with diabetic macular edema (TYBEE) clinicaltrials.gov\/show\/NCT03126786"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0020|cit20","unstructured":"UMIN000021630 Anti-VEGF and steroid combination therapy for diabetic macular edema apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000021630"},{"issue":"4","key":"10.1002\/14651858.CD011599.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00417-007-0688-0","article-title":"Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial","volume":"246","author":"Ahmadieh","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011599.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/eye.2015.110","article-title":"A review of therapies for diabetic macular oedema and rationale for combination therapy","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"issue":"13","key":"10.1002\/14651858.CD011599.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"6921","key":"10.1002\/14651858.CD011599.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD011599.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00006324-197611000-00006","article-title":"New design principles for visual acuity letter charts","volume":"53","author":"Bailey","year":"1976","journal-title":"American Journal of Optometry and Physiological Optics"},{"issue":"12","key":"10.1002\/14651858.CD011599.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2015.12.012","article-title":"Bevacizumab or dexamethasone implants for DME: 2-year results (The BEVORDEX Study)","volume":"123","author":"Fraser-Bell","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011599.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"issue":"7","key":"10.1002\/14651858.CD011599.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.eye.6702767","article-title":"Causes of blind certifications in England and Wales: April 1999-March 2000","volume":"22","author":"Bunce","year":"2008","journal-title":"Eye"},{"issue":"10","key":"10.1002\/14651858.CD011599.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0033|cit33","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011599.pub2-BIB0034|cit34","first-page":"807","article-title":"Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema","volume":"110","author":"Funatsu","year":"2003","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011599.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":"Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD011599.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2182-7","DOI":"10.1016\/j.ophtha.2009.04.049","article-title":"Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011599.pub2-BIB0038|cit38","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD011599.pub2-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656.pub2","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0040|cit40","unstructured":"Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0041|cit41","volume-title":"Diabetes Atlas","author":"International Diabetes Federation","year":"2011"},{"issue":"9600","key":"10.1002\/14651858.CD011599.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011599.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.survophthal.2012.10.002","article-title":"Medical management for the prevention and treatment of diabetic macular edema","volume":"58","author":"Kiire","year":"2013","journal-title":"Survey of Ophthalmology"},{"issue":"9614","key":"10.1002\/14651858.CD011599.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(08)60332-3","article-title":"Fenofibrate and diabetic retinopathy","volume":"371","author":"Liew","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD011599.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/bjophthalmol-2015-307797","article-title":"Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial","volume":"100","author":"Mehta","year":"2016","journal-title":"British Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(98)96025-0","article-title":"The 14-year incidence of visual loss in a diabetic population","volume":"105","author":"Moss","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0047|cit47","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"9","key":"10.1002\/14651858.CD011599.pub2-BIB0048|cit48","first-page":"533","article-title":"Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes","volume":"65","author":"Scheen","year":"2010","journal-title":"Revue Medicale de Liege"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0049|cit49","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011599.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD011599.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jcjo.2013.11.012","article-title":"Vitrectomy for diabetic macular edema: a systematic review and meta-analysis","volume":"49","author":"Simunovic","year":"2014","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","article-title":"Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema","volume":"116","author":"Soheilian","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD011599.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011599.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub5","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011599.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1248\/bpb.31.1541","article-title":"Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression","volume":"31","author":"Wang","year":"2008","journal-title":"Biological and Pharmaceutical Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD011599.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/bjophthalmol-2016-309882","article-title":"Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema","volume":"101","author":"Wickremasinghe","year":"2017","journal-title":"British Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011599.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0b013e31817e100f","article-title":"Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease","volume":"28","author":"Wong","year":"2008","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD011599.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/2008-322X.150818","article-title":"Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial","volume":"9","author":"Yaseri","year":"2014","journal-title":"Journal of Ophthalmic and Vision Research"},{"issue":"3","key":"10.1002\/14651858.CD011599.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011599.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011599","article-title":"Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema","author":"Mehta","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011599.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T15:03:59Z","timestamp":1626534239000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011599.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011599.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733074451.793546813","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]}}}